| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 10/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name: | Crizotinib |
| CAS: | 877399-52-5 |
| MF: | C21H22Cl2FN5O |
| MW: | 450.343 |
| Purity: | 99% min |
| Appearance: | White Crystalline Powder |
| MOQ: | 10 grams |
| Storage: | Store in a cool, dry place |
| Deliver time: | About 5 days |
| Deliver methods: | By express (door to door) |
Crizotinib (trade name Xalkori,) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy inanaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
Crizotinib has an aminopyridine structure, and functions as a protein kinase inhibitor by competitive binding within the ATP-binding pocket of target kinases. About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion genebetween EML4 ('echinoderm microtubule-associated protein-like 4') andALK ('anaplastic lymphoma kinase'), which results in constitutivekinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. The kinase activity of the fusion protein is inhibited by crizotinib. Patients with this gene fusion are typically younger non-smokers who do not have mutations in either theepidermal growth factor receptor gene (EGFR) or in the K-Ras gene.The number of new cases of ALK-fusion NSLC is about 9,000 per year in the U.S. and about 45,000 worldwide.
Treating certain types of lung cancer. It may also be used for other conditions as determined by your doctor.
Crizotinib is a tyrosine kinase inhibitor. It works by preventing the growth of cancer cells.
Crizotinib inhibits the c-Met (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms.
Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.
){kind=link}